Recent News

• 04.21.2025 - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
• 04.21.2025 - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
• 04.17.2025 - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
• 04.17.2025 - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
• 03.10.2025 - Leerink’s Global Healthcare Conference
• 03.10.2025 - Leerink’s Global Healthcare Conference
• 03.10.2025 - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.10.2025 - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.03.2025 - Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
• 03.03.2025 - Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

Recent Filings

• 03.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - 8-K Current report
• 02.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - 3 Initial statement of beneficial ownership of securities
• 01.13.2025 - 8-K Current report
• 01.13.2025 - EX-99.1 EX-99.1
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities